Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | FDFT1 | P37268 | 9/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106368 | 0.88 | POLB (0.68) | FDFT1AKR1C3POLBMTNR1AMTNR1B | |
| SCHEMBL10106243 | 0.84 | FDFT1 (0.56) | FDFT1AKR1C3 | |
| SCHEMBL28028806 | 0.82 | MEN1 (0.90) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL10106156 | 0.80 | MTNR1A (0.76) | FDFT1MTNR1AMTNR1B | |
| SCHEMBL6795855 | 0.78 | LTA4H (0.55) | FDFT1ALDH1A1 | |
| SCHEMBL12721428 | 0.77 | SMN1; SMN2 (0.62) | AKR1C3MTNR1AMTNR1B | |
| SCHEMBL8970829 | 0.77 | FDFT1 (0.55) | FDFT1ALDH1A1 | |
| SCHEMBL10106173 | 0.76 | MTNR1A (0.70) | FDFT1MTNR1AMTNR1B | |
| SCHEMBL10106193 | 0.76 | PPARA (0.60) | FDFT1 | |
| SCHEMBL8977543 | 0.76 | FDFT1 (0.55) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | CUTA, MMP8, CLPP | MEN1 4323/4885KMT2A 4262/4885FDFT1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.